

## Curriculum Vitae of David B. Ross, M.D., Ph.D., M.B.I.

### **Personal data**

Citizenship: United States

Telephone: (301) 500-8557

E-mail: [rossmdpharmaexpert@gmail.com](mailto:rossmdpharmaexpert@gmail.com)

### **Education**

**1980** B.S. *cum laude* (Molecular Biophysics and Biochemistry), Yale University

**1985** M.S. (Biochemistry), New York University

**1988** Ph.D. (Biochemistry), New York University. Thesis advisor: Edward Ziff, Ph.D. Thesis title: "Defective processing of human adenovirus 2 messenger RNA during abortive infections in monkey cells."

**1988** M.D., New York University School of Medicine

**2008** Graduate Certificate in Biomedical Informatics, Oregon Health and Sciences University

**2012** Master of Biomedical Informatics program, Oregon Health and Sciences University. Advisor: Judy Logan, M.D. Capstone title: "An antibiogram data model and implementation schema."

### **Post-doctoral training**

**1988-1991** Resident, Internal Medicine, NYU Medical Center/Manhattan VAMC

**1991-1994** Fellow, Infectious Disease Section, Department of Internal Medicine, Yale University School of Medicine

**1992-1994** Research Fellow, Division of Infectious Diseases, Department of Pediatrics, Yale University School of Medicine

### **FDA Training**

**1996** CDER Regulatory Science Course; CDER New Reviewer's Workshop

**1997** CBER Clinical Trials Course

**FDA Training (cont.)**

- 1998** CDER Basic Statistical Methods Course; JMP Training
- 2003** FDA Pharmacogenomics in Drug Development Workshop
- 2005** FDA Transcriptional Microarrays Course

**Expert Witness Training**

- 2014** How to be an Effective Expert Witness. SEAK, Inc., Feb 8-9, Clearwater, FL
- 2015** National Expert Witness Conference. SEAK, Inc., Apr 23-26, Washington, DC
- 2016** Advanced Trial Skills for Expert Witnesses. SEAK, Inc., May 12-13, Chicago, IL
- 2016** National Expert Witness Conference. SEAK, Inc., May 14-15, Chicago, IL
- 2018** How to Excel at Your Expert Witness Deposition. SEAK, Inc., Dec 1-2, Naples, FL

**Professional Experience**

- 2006-** Director, HIV, Hepatitis and Related Conditions Programs, Office of Specialty Care Services, Veterans Health Administration
- 2005-2006** Associate Director for Regulatory Science, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
- 2004-2005** Deputy Director, Office of Drug Evaluation VI, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
- 2003-2004** Medical Team Leader, Division of Anti-Infective Drug Products, Center for Drug Evaluation and Research, U. S. Food and Drug Administration
- 2000-2004** Senior Medical Reviewer, Division of Anti-Infective Drug Products, Center for Drug Evaluation and Research, U. S. Food and Drug Administration

### **Professional Experience (cont.)**

- 1999** Acting Medical Team Leader, Division of Anti-Infective Drug Products, Center for Drug Evaluation and Research, U. S. Food and Drug Administration
- 1998-Present** Staff Physician, Infectious Disease Section, Washington, DC VAMC
- 1996-2004** Medical Officer, Division of Anti-Infective Drug Products, Center for Drug Evaluation and Research, U. S. Food and Drug Administration
- 1995-1996** Associate Physician, Department of Pediatrics, Yale-New Haven Hospital; Attending Physician, Pediatric AIDS Clinic, Yale-New Haven Hospital
- 1994-1996** Staff Physician, Infectious Disease Section, West Haven, Connecticut VAMC
- 1993-1997** Infectious Disease Consultant, HIV in-Prisons Program, Yale University School of Medicine
- 1991-1993** Emergency Room Attending (Medical Officer of the Day), Manhattan VAMC

### **Academic Positions**

- 2008-Present** Associate Clinical Professor of Medicine, George Washington University School of Medicine and Health Sciences
- 2000-2008** Assistant Clinical Professor of Medicine, George Washington University School of Medicine and Health Sciences
- 1995-1996** Instructor, Department of Pediatrics (Infectious Diseases), Yale University School of Medicine
- 1992-1993** Lecturer, Department of Molecular Biophysics and Biochemistry, Yale University
- 1989-1991** Teaching Assistant, Department of Medicine, NYU School of Medicine

### **Honors and awards**

- 2006** CDER Excellence in Communication Award (OODP)
- 2005** CDER Excellence in Leadership Award (ODE VI)
- 2004** CDER Team Excellence Award (Ketek Review Team)

**Honors and awards (cont.)**

- 2003** CDER Team Excellence Award (CDER TOPOFF 2 Exercise Team)
- 2002** FDA Award of Merit (CDER Counter-Terrorism Response Team)
- 2000** FDA Commendable Service Award (Linezolid Review Team)
- 1999** CDER Group Recognition Award (Inter-Divisional Working Group on Antibiotic Resistance)
- 1997** CDER Team Excellence Award (Maxipime® Review Team)
- 1997** CDER Excellence in Communication Award (CDER/PhRMA Working Group)
- 1994-1996** Pediatric AIDS Foundation Scholar
- 1992-1994** Patrick and Catherine Weldon Donaghe Medical Research Foundation Fellow
- 1980-1987** National Institutes of Health Medical Scientist Training Fellow
- 1976** U.S. Presidential Scholar

**Licenses and Certification**

- 1989** Diplomate, National Board of Medical Examiners
- 1989** Licensed, New York State Board for Medicine (inactive)
- 1992** Diplomate in Internal Medicine, American Board of Internal Medicine
- 1993** Licensed, State of Connecticut Department of Health Services (inactive)
- 1994** Diplomate in Infectious Diseases, American Board of Internal Medicine
- 1998** Licensed, State of Maryland Board of Physician Quality Assurance (current)
- 2002** Recertification in Internal Medicine, American Board of Internal Medicine
- 2004** Recertification in Infectious Diseases, American Board of Internal Medicine

**Licenses and Certification (cont.)**

**2015** Recertification in Infectious Diseases, American Board of Internal Medicine

**Membership in Professional Societies**

American College of Physicians

Infectious Diseases Society of America

- Antimicrobial Use and Clinical Trials Committee (2001 – 2005)
- Antimicrobial Availability Task Force (2003 – 2005)

**FDA Advisory Committee and Workshop Presentations**

**March 2006** Oncology Drugs Advisory Committee Presenter (Nonclinical Studies for Initiating Phase 1 Studies in Oncology: Small Molecules vs Biologics)

**June 2004** Public Workshop on Strategies for Developing Therapeutics that Directly Target Anthrax and its Toxins (Clinical Safety Testing in Healthy Volunteers)

**April 2004** Public Workshop on Antimicrobial Drug Development (Bacteremia as an Indication)

**October 2003** Anti-Infective Drug Products Advisory Committee Presenter (Diabetic Foot Infections)

**February 2002** Anti-Infective Drug Products Advisory Committee Presenter (Developing Drugs for Resistant Pathogens)

**April 2001** Anti-Infective Drug Products Advisory Committee Presenter (Ketek (telithromycin))

**March 2000** Anti-Infective Drug Products Advisory Committee Presenter (Zyvox (linezolid))

**October 1999** Anti-Infective Drug Products Advisory Committee Presenter (Guidance for Industry. Catheter-related bloodstream infections: Developing antimicrobials for treatment)

**July 1999** Federal interagency meeting – Development of a Public Health Action Plan to Combat Antimicrobial Resistance

**October 1998** Anti-Infective Drug Products Advisory Committee Presenter (Bacteremia as an Indication)

**FDA Advisory Committee and Workshop Presentations (cont.)**

**July 1998** FDA-Industry Workshop on Anti-Infectives for Resistant Bacteria

**February 1998** Anti-Infective Drug Products Advisory Committee Presenter (Guidance for Industry. Empiric therapy of febrile neutropenia: Developing antimicrobials for treatment)

**March 1997** Anti-Infective Drug Products Advisory Committee Presenter (Maxipime (cefepime) for empiric therapy of febrile neutropenia)

**November 1996** Anti-Infective Drug Products Advisory Committee Presenter (Closed meeting)

**FDA Special Assignments**

**2004 – 2005** Anthrax Toxin Therapeutic Guidance Working Group (chair)

**2004 – 2006** Subpart D Working Group

**2004 – 2006** Lead in Drug Products Working Group

**1999 – 2002** Committee for the Advancement of FDA Science

**1999** Catheter-related Bloodstream Infections Guidance Working Group (chair)

**1997 – 1999** CDER ODE IV Evaluability Criteria Working Group


**1997** CDER ODE IV Working Group on Drugs of Last Resort (chair)

**1997** CDER ODE IV Task Force on Human Antibiotic Use in Animals

**1997** CDER ORM Information Technology Working Group

**1997** CDER ODE IV/PhRMA Working Group on Targeted Package Inserts

CDER Office of Information Technology Coordinating Committee



## **Presentations**

**Hepatitis C in the Department of Veterans Affairs.** American Correctional Association All-Health Authority Training Symposium, November 15, 2018.

**Ending the Epidemic: Veterans Administration Strategy for Hepatitis Care.** Kentucky 4<sup>th</sup> Annual Viral Hepatitis Conference, July 27, 2017.

**HIV in VA – Where are we?** Albany Medical College, World AIDS Day Conference, December 4, 2015.

**Hepatitis C in VA.** U.S. Department of Health and Human Services, World Hepatitis Day Conference. July 28, 2015.

**Hepatitis C Drug Costs.** Testimony at Hearing before Senate Veteran Affairs Committee. 113<sup>th</sup> Congress, Second Session. December 3, 2014.

**Hepatitis C in VA.** National Association of State Medicaid Directors. November 6, 2014.

**HIV Testing in the U.S. Department of Veterans Affairs.** Pennsylvania Department of Public Health Conference on HIV surveillance. October 30, 2014.

**Hepatitis C and Cirrhosis.** VHA National Transplant Conference. April 23, 2014.

**Viral Structure, Genetics, and Pathogenesis.** George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 6, 2013.

**VHA's National Hepatitis C Program.** Briefing for House and Senate Veterans Affairs Committee staff. October 11, 2013.

**Hepatitis C in the Department of Veterans Affairs.** Hospital of the University of Pennsylvania Grand Rounds. September 18, 2013.

**Restructuring the VHA's Field-Based HCV Program.** Presentation to the VHA National Leadership Council. August 20, 2013

**Viral Structure and Replication.** George Washington University School of Medicine and Health Sciences, Infection and Immunity course, March 20, 2013.

**Viral Structure, Genetics, and Pathogenesis.** George Washington University School of Medicine and Health Sciences, Medical Microbiology course. October 31, 2012.

**Presentations (cont.)**

**VHA's National HIV Program.** Briefing for staff in office of Representative Barbara Lee (9<sup>th</sup> Congressional District, California). March 15, 2012

**Viral Structure, Genetics, and Pathogenesis.** George Washington University School of Medicine and Health Sciences, Medical Microbiology course. October 26, 2011.

**HIV Testing in VA.** Indian Health Service HIV/STD Workshop, Scottsdale, AZ, June 2, 2011.

**HCV in the VA in 2011: Where are we?** VISN 16 Pharmacy Benefits Management Strategic Planning Meeting, Ridgeland, MS, March 9, 2011.

**Viral Structure and Replication.** George Washington University School of Medicine and Health Sciences, Infection and Immunity course, February 8, 2011.

**HIV and HCV: Rating Disabilities in Veterans with Service-Connected HIV or HCV.** Veterans Benefit Administration Service-Connected Rating Disability Forum, Scottsdale, AZ, January 31, 2011.

**HCV in the VA in 2010: Where are we?** Infectious Disease Grand Rounds, Durham Veterans Affairs Medical Center, December 13, 2010.

**Viral Structure, Genetics, and Pathogenesis.** George Washington University School of Medicine and Health Sciences, Medical Microbiology course. October 28, 2010.

**HCV in the U.S. Department of Veterans Affairs.** Professor *pro tem* Lecture, University of Mississippi Medical Center, September 22, 2010.

**Hepatitis C Overview.** Liver Disease for VA Primary Care Providers meeting, New Orleans, June 16, 2010.

**HCV in the VA in 2010: Where are we?** Grand Rounds, Temple (TX) Veterans Affairs Medical Center, June 10, 2010.

**HCV in the VA in 2010: Where are we?** Grand Rounds, Dallas Veterans Affairs Medical Center, January 27, 2010.

**HCV in the VA in 2009: Where are we?** Grand Rounds, Orlando Veterans Affairs Medical Center, December 2, 2009.



**Presentations (cont.)**

**Viral Structure, Genetics, and Pathogenesis.** George Washington University School of Medicine and Health Sciences, Medical Microbiology course. October 29, 2009.

**Impact of Comorbidities on the Management and Prognosis of Chronic Liver Disease.** Presented at **The Dawn of a New Era: Transforming our Domestic Response to Hepatitis B & C**, September 14, 2009.

**HCV in the VA in 2009: Where are we?** Grand Rounds, Bay Pines Veterans Affairs Medical Center, September 2, 2009.

**HIV Care in the Department of Veterans Affairs.** Grand Rounds, University of Mississippi Medical Center, July 21, 2009.

**HCV in the VA in 2009: Where are we?** Grand Rounds, Pensacola, Florida Joint Ambulatory Care Center, June 25, 2009.

**HIV in the VA in 2009: Where are we?** Grand Rounds, Salem, Virginia Veterans Affairs Medical Center, March 4, 2009.

**HIV in the VA in 2009: Where are we?** Grand Rounds, Gulf Coast Veterans Healthcare System. March 11, 2009.

**Viral Structure, Genetics, and Pathogenesis.** George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 7, 2008.

**Ketek: Lessons Learned.** Clinical Operations Retreat, May 8, 2008.

**Pharmacogenomics: A Guide for the Perplexed.** Grand Rounds, Sinai Hospital (Baltimore, MD). March 27, 2008.

**Ketek Clinical Study Fraud: What did Aventis Know?** Testimony at Hearing Before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce. 110th Congress, Second Session. February 14, 2008.

**Viral Structure, Genetics, and Pathogenesis.** George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 2, 2007.

**FDA: Inside the Black Box.** George Washington University School of Public Health and Health Services. October 29, 2007.

**Viral Structure, Genetics, and Pathogenesis.** George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 3, 2006.

**Presentations (cont.)**

**The Good, the Bad, and the Unbelievable: Interpreting Clinical Trials.**

Grand Rounds, Washington, D.C. Veteran's Affairs Medical Center.  
October 25, 2006.

**Oncology Biomarkers for Safety and Efficacy.** 2006 International  
Conference on Drug Development. February 15, 2006

**Pharmacogenomics: A Guide for the Perplexed.** Grand Rounds  
Washington, D.C. Veteran's Affairs Medical Center. January 18, 2006.

**Issues in accelerated approval.** 12th Biomedical Applied Statistics  
Symposium. November 9, 2005.

**FDA's Critical Path Initiative.** 2005 Annual Meeting of the Association of  
Clinical Research Professionals. November 4, 2005

**Natalizumab: A case study in classic risk-benefit analysis.**  
Biotechnology Industry Organization annual meeting. June 21, 2005.

**Therapeutic Biologics.** Pharmaceutical Education and Research Institute  
course on "Biologics Drug Development." April 11, 2005

**Therapeutic Biologics.** University of Maryland, Baltimore course on "Drug  
Development Processes and Regulatory Approaches." March 23, 2005.

**FDA's Critical Path Initiative.** Association of Clinical Research  
Professionals (Connecticut Chapter). March 9, 2005.

**Bone and Joint Infections.** GWUMC/Washington DC VAMC Fellows  
Lecture program. December 23, 2004.

**Viral Structure, Genetics, and Pathogenesis.** George Washington  
University School of Medicine and Health Sciences, Medical Microbiology  
course. November 5, 2004.

**Viral Structure, Genetics, and Pathogenesis.** George Washington  
University School of Medicine and Health Sciences, Medical Microbiology  
course. November 3, 2003.

**Bone and Joint Infections.** GWUMC/Washington DC VAMC Fellows  
Lecture program. June 26, 2003.

**Viral Structure, Genetics, and Pathogenesis.** George Washington  
University School of Medicine and Health Sciences, Medical Microbiology  
course. November 4, 2002.

**Presentations (cont.)**

**Bone and Joint Infections.** GWUMC/Washington DC VAMC Fellows Lecture program. May 23, 2002.

**The Role of Antibiotics in Upper Respiratory Tract Infections.** Grand Rounds, Washington, D.C. Veteran's Affairs Medical Center. February 6, 2002.

**Clinical Trials – the FDA perspective.** 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. December 18, 2001.

***Catheter-related Bloodstream Infections: Developing Antimicrobial Drugs for Treatment.*** 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. December 16, 2001.

**Geriatric Drug Development.** American College of Toxicology, 22<sup>nd</sup> Annual Meeting. November 6, 2001.

**Viral Structure, Genetics, and Pathogenesis.** George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 2, 2001.

**Don't Let Your Patients Push You to Prescribe: Managing the Use of Antibiotics.** Maryland State Medical Association 2001 Convention. September 8, 2001.

**Cotrimoxazole and Lactation.** CDER Scientific Rounds. April 19, 2001

**Treatment of Gram-positive Infections in the New Millennium.** Washington, D.C. Veteran's Affairs Medical Center. February 8, 2001.

**Viral Structure, Genetics, and Pathogenesis.** George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 1, 2000.

**Comparators in Clinical Trials.** 38<sup>th</sup> Infectious Diseases Society of America Annual Meeting. September 7, 2000.

**New Antimicrobials for Drug-Resistant Gram-Positive Organisms.** Washington, D.C. Veteran's Affairs Medical Center. May 26, 2000.

**Bone and Joint Infections.** GWUMC/DC VAMC Fellows Lecture program. May 18, 2000.

**Viral Structure and Genetics.** George Washington University School of Medicine and Health Sciences, Medical Microbiology course. November 16, 1999.

**Presentations (cont.)**

**Clinical Trials: The FDA Perspective.** George Washington University Medical Center, Clinical Trials course. October 1, 1999.

**Use of alternative definitions of clinical response in trials of empiric anti-bacterial therapy of febrile episodes in neutropenic patients.** 39<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy. September 27, 1999.

**Skin and Soft Tissue Infections.** Washington Hospital Center/Washington VAMC Fellows Lecture program. December 17, 1998.

**Computer-Assisted New Drug Applications.** FDA Office of the Commissioner's Administrative Conference. December 6, 1996.

**FDA: Inside the Black Box.** Yale University, Department of Molecular Biophysics and Biochemistry, November 12, 1996.

**EXPERT NOT RETAINED**

## **Publications**

### **Books and Book Chapters**

1. **Ross D, ed.** Primary Care of Veterans with HIV, revised edition. (Washington, DC: US Department of Veterans Affairs), 2019.
2. **Ross D, ed.** Primary Care of Veterans with HIV edition. (Washington, DC: US Department of Veterans Affairs), 2009.
3. **Ross D** and Trevino S. Bacteremia and sepsis. *In* Textbook of Diagnostic Microbiology, 3rd edition (New York: W.B. Saunders), 2007. Eds. C. Mahon and G. Manuselis.

### **Published Articles**

1. Yakovchenko V, Miech EJ, Chinman MJ, Chartier M, Gonzalez R, Kirchner JE, Morgan TR, Park A, Powell BJ, Proctor EK, **Ross D**, Waltz TJ, Rogal SS. Strategy Configurations Directly Linked to Higher Hepatitis C Virus Treatment Starts: An Applied Use of Configurational Comparative Methods. *Med Care.* 2020;58(5):e31-e38.
2. Rogal SS, Yakovchenko V, Waltz TJ, Powell BJ, Gonzalez R, Park A, Chartier M, **Ross D**, Morgan TR, Kirchner JE, Proctor EK, Chinman MJ. Longitudinal assessment of hepatitis C treatment: Year 2. *Implement Sci.* 2019 Apr 8;14(1):36.
3. Butt AA, Yan P, Lo Re Iii V, Shaikh OS, **Ross DB**. Trends in Treatment Uptake and Provider Specialty for Hepatitis C Virus (HCV) Infection in the Veterans Affairs Healthcare System: Results from the Electronically Retrieved Cohort of HCV-Infected Veterans (ERCOHIVES). *Clin Infect Dis.* 2019 Feb 15; 68(5):857-859.
4. Belperio PS, Chartier M, Gonzalez RI, Park AM, **Ross DB**, Morgan TR, Backus LI. Hepatitis C Care in the Department of Veterans Affairs: Building a Foundation for Success. *Infect Dis Clin North Am.* 2018 Jun; 32(2):281-292.
5. Bajaj JS, **Ross D**. Concise Commentary: Remaining Outside the Hospital Is a Golden State in Cirrhosis-Lessons from California. *Dig Dis Sci.* 2018 Sep; 63(9):2275-6.
6. Belperio PS, Chartier M, **Ross DB**. After Curing Hepatitis C Infection. *Ann Intern Med* 2018; 168(9):682-3.

**Published articles (cont.)**

7. Park A, Gonzalez R, Chartier M, Rogal S, Yakovchenko V, **Ross D**, Morgan TR. Screening and Treating Hepatitis C in the VA: Achieving Excellence Using Lean and System Redesign. *Fed Pract*. 2018 Jul; **35(7)**:24-29.
8. Chartier M, Maier MM, Morgan TR, Lowy E, Hoffman-Högg J, **Ross D**, Beste LA. Achieving Excellence in Hepatitis B Virus Care for Veterans in the Veterans Health Administration. *Fed Pract*. 2018 Mar; **35(Suppl 2)**:S49-S53.
9. Belperio PS, Chartier M, **Ross DB**, Alaigh P, Shullkin D. Caring for Hepatitis C Virus Infection: Best Practices From the U.S. Department of Veterans Affairs. *Ann Intern Med* 2017 Oct 3; **167(7)**:499-504.
10. Rogal SS, Yakovchenko V, Waltz TJ, Powell RJ, Kirchner JE, Proctor EK, Gonzalez R, Park A, **Ross D**, Morgan TR, Chartier M, Chinman MJ. The association between implementation strategy use and the uptake of hepatitis C treatment in a national sample. *Implement Sci* 2017 May 11; **12(1)**:60.
11. Beste LA, Glorioso TJ, Ho PM, Xu DH, Kirsh SR, Todd-Stenberg J, Chang MF, Dominitz JA, Barrón AE, **Ross D**. Telemedicine Specialty Support Promotes Hepatitis C Treatment by Primary Care Providers in the Department of Veterans Affairs. *Am J Med* 2017; **130(4)**:432-8.
12. **Ross DB**, Belperio PS, Chartier M, Backus LI. Hepatitis C Testing in US Veterans Born 1945-1965: An Update. *J Hepatol* 2017; **66(1)**:21-8.
13. Maier MM, **Ross DB**, Chartier M, Belperio PS, Backus LI. Cascade of Care for Hepatitis C Virus Infection Within the US Veterans Health Administration. *Am J Public Health* 2016 Feb; **106(2)**:353-8.
14. Beste LA, Leipertz SL, Green PK, Dominitz JA, **Ross D**, Ioannou GN. Trends in Burden of Cirrhosis and Hepatocellular Carcinoma by Underlying Liver Disease in US Veterans, 2001-2013. *Gastroenterology*. 2015 Nov; **149(6)**:1471-1482.

**Published articles (cont.)**

15. Backus L, Czarnogorski M, Yip G, Thomas BP, Torres M, Bell T, **Ross D.** HIV Care Continuum Applied to the US Department of Veterans Affairs: HIV Virologic Outcomes in an Integrated Health Care System. *J Acquir Immune Defic Syndr.* 2015 Aug 1; **69(4):**474-80.
16. Chartier M, Blais R, Steinberg T, Catella S, Dehon S, **Ross D,** Zetterstrom R. A Postdoctoral Psychology Fellowship in Integrated Health and Hepatitis C Clinical Care: Rationale, Progress, and Future Directions. *Training and Education in Professional Psychology.* 2015 May; **9(2):**77-84.
17. Beste LA, Ionnou GN, Yang Y, Chang M, **Ross D,** Dominitz J. Improved Surveillance for Hepatocellular Carcinoma with a Primary Care-Oriented Clinical Reminder. *Clin Gastroenterol Hepatol.* 2015 Jan; **13(1):**172-9.
18. Midboe AM, Elwy AR, Durfee JM, Gifford AL, Yakovchenko V, Martinello RA, **Ross D,** Czarnogorski M, Goetz MB, Asch SM. Building Strong Research Partnerships Between Public Health and Researchers: A VA Case Study. *J Gen Intern Med.* 2014 Dec; **29 Suppl 4:**831-4.
19. Atkins D, **Ross D,** Kelley M. Acting in the Face of Uncertainty. *Ann Intern Med* 2014; **161(4):**300-1.
20. Belperio P, Backus L, **Ross D,** Neuhauser M, Mole L. A Population Approach to Disease Management: Hepatitis C Direct Acting Antiviral Use in a Large Healthcare System. *J Managed Care Pharm* 2014 Jul; **20(6):**533-40.
21. Czarnogorski M, Halloran J, Pedati C, Dursa EK, Durfee J, Martinello R, Davey V, **Ross D.** Expanded HIV testing in the US Department of Veterans Affairs, 2009-2011. *Am J Public Health* 2013 Dec; **103(12):**e40-5.
22. **Ross D.** Treatment of veterans with hepatitis C in the United States Department of Veterans Affairs. *J Hepatol* 2013 Jul; **59(1):**196.

**Published articles (cont.)**

23. Yee HS, Chang MF, Pocha C, Lim J, **Ross D**, Morgan TR, Monto A. Update on the Management and Treatment of Hepatitis C Virus Infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. *Am J Gastroenterol* 2012; **107(5)**:669-89.
24. Halloran J, Czarnogorski M, Dursa E, Volpp B, Durfee J, Valdiserri R, Davey V, **Ross D**. HIV Testing in the US Department of Veterans Affairs: 2009-2010. *Arch Int Med* 2012 Jan 9; **172(1)**:61-2.
25. McInnes DK, Solomon JL, Bokhour BG, Asch SM, **Ross D**, Nazi KM, Gifford AL. Use of electronic personal health record systems to encourage HIV screening: an exploratory study of patient and provider perspectives. *BMC Res Notes* 2011 Aug 15; **4**:295.
26. Peters MG, Perrillo RP, Jacobson IM, **Ross D**, Doo EC, Murray JS, Wong JB. Entering the new era of therapy for HBV and HCV infections. *J Fam Pract* 2010 Apr; **59(4 Suppl)**:S51-8.
27. Valdiserri RO, Nazi K, McInnes DK, **Ross D**, Kinsinger L. Need to improve routine HIV testing of U.S. Veterans in care: Results of an Internet survey. *J Community Health* 2010; **35(3)**:215-9.
28. Garcia-Tsao G, Lim J, Monto A, Yee H, Durfee J, Dieperink E, Dominitz J, **Ross D**, Valdiserri R. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. *Am J Gastroenterol* 2009 Jul; **104(7)**:1802-29.
29. **Ross D**, Kan V. Macrolide and Clindamycin Resistance in *Staphylococcus aureus* Isolates. *Infect Control Hosp Epidemiol* 2008; **29**:180-2.
30. **Ross D**. Review of “Overdose: How excessive government regulation stifles pharmaceutical innovation.” *J Clin Invest* 2007; **117**:3598-3598
31. **Ross D**. The FDA and the case of Ketek. *New Engl J Med* 2007; **356**:1601-1604.
32. Powers JH, Lin D, **Ross D**. FDA evaluation of antimicrobials: subgroup analysis. *Chest* 2005; **127**: 2298-9.



**Published articles (cont.)**

33. Powers JH, Cooper CK, Lin D, **Ross DB**. Sample size and the ethics of non-inferiority trials. *Lancet*. 2005; **366**:24-5.
34. Powers JH, **Ross DB**, Lin D. Letter to the Editor: Linezolid and Vancomycin for Methicillin-Resistant *Staphylococcus aureus* Nosocomial Pneumonia: The Subtleties of Subgroup Analyses. *Chest* 2004; **126**:314-315.
35. Powers JH, **Ross DB**, Brittain E, Albrecht R, and Goldberger N. The United States Food and Drug Administration and Noninferiority Margins in Clinical Trials of Antimicrobial Agents. *Clin Infect Dis* 2002; **34**:879-881.
36. Qunibi W, Al-Furayh O, Almeshari K, Lin S-F, Sun H, Heston L, **Ross D**, Rigsby M, and Miller G. Serologic association of human herpesvirus eight with posttransplant Kaposi's sarcoma in Saudi Arabia. *Transplantation* 1998; **65**:580-583.
37. **Ross DB** and Ziff EB. Differential production of human adenovirus late transcription unit mRNAs during abortive infections in monkey cells. *Virology* 1994; **202**:109-115.
38. **Ross DB** and Ziff EB. Defective synthesis of early region 4 mRNAs during abortive human adenovirus infections in monkey cells. *J Virol* 1992; **66**:3110-3117.

EXPERT NOT RETAINED